Trazodone for Bipolar Patients
Trazodone can be used safely as a sleep aid in bipolar patients who are stable on mood stabilizers, particularly at low doses (25-75 mg), with minimal risk of inducing mania when combined with mood stabilizer therapy.
Evidence-Based Recommendation
The FDA label explicitly warns that trazodone may precipitate mania/hypomania in patients with bipolar disorder, stating "activation of mania/hypomania has been reported in a small proportion of patients with major affective disorder who were treated with antidepressants" 1. However, this warning must be contextualized with clinical evidence and dosing considerations.
Key distinction: The risk of switching to mania is dose-dependent and dramatically reduced when:
- Low doses (25-75 mg) are used specifically for sleep rather than antidepressant doses (150-300 mg)
- The patient is concurrently taking a mood stabilizer
- The patient's bipolar disorder is currently stable
Clinical Evidence Supporting Safe Use
A systematic review specifically examining switch risk found that low doses of trazodone used for hypnotic/sedative effects caused mania only in patients with other risk factors for switching 2. Critically, there is no evidence that trazodone increases switching risk when administered in combination with a mood stabilizer 2. The authors concluded that low-dose trazodone is safe in bipolar disorder and should be considered an important alternative to hypnotics for long-term insomnia treatment 2.
Practical Implementation Algorithm
Step 1: Verify mood stabilizer coverage
- Confirm the patient is on therapeutic doses of lithium, valproate, lamotrigine, or an atypical antipsychotic
- Do not use trazodone as monotherapy in bipolar patients
Step 2: Dose appropriately
- Start at 25-50 mg at bedtime
- Maximum dose for sleep: 75-100 mg
- Avoid antidepressant doses (≥150 mg) unless specifically treating bipolar depression with adequate mood stabilizer coverage
Step 3: Monitor for early warning signs
- Decreased need for sleep (not just insomnia)
- Increased energy, racing thoughts, or irritability
- Impulsive behavior or increased goal-directed activity
Important Caveats and Contraindications
Cardiac considerations: The FDA label warns that trazodone prolongs QT/QTc interval and should be avoided in patients with known QT prolongation or when combined with other QT-prolonging medications 1. This is particularly relevant as some mood stabilizers and antipsychotics also affect cardiac conduction.
Other FDA warnings to consider:
- Orthostatic hypotension (monitor blood pressure changes)
- Priapism risk in men (discontinue immediately if erection >4 hours)
- Increased bleeding risk if combined with antiplatelet agents or anticoagulants 1
Alternative Perspective from Insomnia Guidelines
The 2026 AASM insomnia guideline provided a conditional recommendation against trazodone for chronic insomnia due to "insufficient evidence of efficacy, absence of high-quality data, and/or other considerations such as potential risks" 3. However, this recommendation applies to the general insomnia population, not specifically to bipolar patients where the risk-benefit calculation differs—particularly when hypnotics carry their own risks and trazodone's sedating properties at low doses may be preferable to benzodiazepines or Z-drugs in patients requiring long-term treatment.
Bottom Line
For a bipolar patient stable on mood stabilizers with insomnia, trazodone 25-75 mg at bedtime is a reasonable and relatively safe option 2. The key is ensuring adequate mood stabilizer coverage, using appropriately low doses, and monitoring for any signs of mood destabilization. Screen for cardiac risk factors and QT prolongation before initiating 1. This approach balances the FDA's mania warning with real-world clinical evidence showing safety in the specific context of adjunctive low-dose use.